Recent 8-K filings for ABT

• April 17, 2026, 7:59 PM ET litigation materiality 0.65 neutral item 8.01item 9.01

  Abbott reaches settlement in shareholder derivative suit over infant formula; governance reforms, up to $15.85M fees

  Settlement of consolidated derivative action alleging fiduciary breaches and securities violations related to infant formula recall.

• April 16, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Abbott Q1 adj. EPS $1.15, +6% YoY; acquires Exact Sciences; FY guidance $5.38-$5.58

  Q1 GAAP diluted EPS $0.61; adjusted diluted EPS $1.15 (+6% YoY).

• March 23, 2026, 7:59 PM ET M&A materiality 0.90 positive item 8.01item 9.01

  Abbott completes $105/share cash acquisition of Exact Sciences, expanding cancer diagnostics

  Abbott completed acquisition of Exact Sciences for $105/share cash; Exact becomes wholly owned subsidiary.

• March 9, 2026, 7:59 PM ET debt materiality 0.80 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings◈ Material Agreements

  Abbott completes $20B senior notes offering to fund Exact Sciences acquisition

  Issued $20B in eight tranches: Floating Rate Notes due 2029, fixed-rate notes from 3.700% to 5.600% with maturities 2029–2066.

• February 26, 2026, 6:59 PM ET debt materiality 0.80 neutral item 1.01item 9.01 ◈ Material Agreements

  Abbott issues $20B multi-tranche notes; proceeds to fund Exact Sciences acquisition

  Issued $20B in senior notes across 8 tranches: floating and fixed rates from 3.70% to 5.60%, maturities 2029-2066.

• January 22, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Abbott Q4 adj EPS $1.50 (+12% YoY); FY2025 revenue $44.3B; FY2026 adj EPS guide $5.55–$5.80

  Q4 GAAP EPS $1.01, adjusted EPS $1.50 (+12% YoY); revenue $11.46B (+4.4% reported, +3.8% ex-COVID).

• November 20, 2025, 6:59 PM ET M&A materiality 1.00 neutral item 1.01item 7.01item 8.01item 9.01

  Abbott to acquire Exact Sciences for $105/share, total equity value ~$21B

  Abbot buys Exact Sciences for $105 per share in cash; equity value ~$21B, enterprise value ~$23B.

• October 15, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Abbott Q3 sales rise 6.9%; adj. EPS $1.30; reaffirms FY guidance

  GAAP diluted EPS $0.94; adjusted diluted EPS $1.30; reported sales $11.37B, organic growth 5.5% (7.5% ex-COVID testing).

• July 17, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Abbott Q2 adjusted EPS $1.26, sales $11.14B (+7.4%); guides FY adjusted EPS $5.10-$5.20

  GAAP diluted EPS $1.01; adjusted diluted EPS $1.26, double-digit growth YoY.

• April 16, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Abbott Q1 adjusted EPS $1.09, revenue $10.36B (+4% reported); reaffirms FY guidance

  GAAP diluted EPS $0.76; adjusted diluted EPS $1.09 (double-digit YoY growth).

• January 22, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Abbott Q4 organic base business sales +10.1%; FY2025 adj. EPS guidance $5.05-$5.25

  Q4 reported sales $11.0B (+7.2% YoY); organic base business (ex-COVID) grew 10.1%.

• October 16, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Abbott Q3 2024: GAAP EPS $0.94, adj. EPS $1.21; raises FY adj. EPS guidance midpoint

  Reported sales $10.6B (+4.9% reported, +8.2% organic ex-COVID tests); Medical Devices +13.3% organic.

• July 18, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Abbott Q2 adjusted EPS $1.14, revenue $10.4B; raises FY guidance

  GAAP EPS $0.74, adjusted $1.14; revenue $10.4B (+4% reported, +9.3% organic ex-COVID).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.72 · Most common event earnings

9 positive 1 negative 12 neutral

source · ABT on sec.gov